387 related articles for article (PubMed ID: 31226134)
1. Predictors for repeated hyperkalemia and potassium trajectories in high-risk patients - A population-based cohort study.
Adelborg K; Nicolaisen SK; Hasvold P; Palaka E; Pedersen L; Thomsen RW
PLoS One; 2019; 14(6):e0218739. PubMed ID: 31226134
[TBL] [Abstract][Full Text] [Related]
2. Elevated Potassium Levels in Patients With Congestive Heart Failure: Occurrence, Risk Factors, and Clinical Outcomes: A Danish Population-Based Cohort Study.
Thomsen RW; Nicolaisen SK; Hasvold P; Garcia-Sanchez R; Pedersen L; Adelborg K; Egfjord M; Egstrup K; Sørensen HT
J Am Heart Assoc; 2018 May; 7(11):. PubMed ID: 29789332
[TBL] [Abstract][Full Text] [Related]
3. Elevated potassium levels in patients with chronic kidney disease: occurrence, risk factors and clinical outcomes-a Danish population-based cohort study.
Thomsen RW; Nicolaisen SK; Hasvold P; Sanchez RG; Pedersen L; Adelborg K; Egstrup K; Egfjord M; Sørensen HT
Nephrol Dial Transplant; 2018 Sep; 33(9):1610-1620. PubMed ID: 29177463
[TBL] [Abstract][Full Text] [Related]
4. Use of renin angiotensin system inhibitors in patients with chronic kidney disease.
Adam WR; Wright JR
Intern Med J; 2016 May; 46(5):626-30. PubMed ID: 27170242
[TBL] [Abstract][Full Text] [Related]
5. Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors.
Weir MR; Bakris GL; Bushinsky DA; Mayo MR; Garza D; Stasiv Y; Wittes J; Christ-Schmidt H; Berman L; Pitt B;
N Engl J Med; 2015 Jan; 372(3):211-21. PubMed ID: 25415805
[TBL] [Abstract][Full Text] [Related]
6. Prevalence of hyperkalemia in adult patients taking spironolactone and angiotensin converting enzyme inhibitors or angiotensin receptor blockers.
Surabenjawong U; Thunpiphat N; Chatsiricharoenkul S; Monsomboon A
J Med Assoc Thai; 2013 Aug; 96(8):905-10. PubMed ID: 23991595
[TBL] [Abstract][Full Text] [Related]
7. Hyperkalemia and renin-angiotensin aldosterone system inhibitor therapy in chronic kidney disease: A general practice-based, observational study.
Jun M; Jardine MJ; Perkovic V; Pilard Q; Billot L; Rodgers A; Rogers K; Gallagher M
PLoS One; 2019; 14(3):e0213192. PubMed ID: 30845156
[TBL] [Abstract][Full Text] [Related]
8. How prevalent is hyperkalemia and renal dysfunction during treatment with spironolactone in patients with congestive heart failure?
Svensson M; Gustafsson F; Galatius S; Hildebrandt PR; Atar D
J Card Fail; 2004 Aug; 10(4):297-303. PubMed ID: 15309695
[TBL] [Abstract][Full Text] [Related]
9. Hyperkalemia-Related Discontinuation of Renin-Angiotensin-Aldosterone System Inhibitors and Clinical Outcomes in CKD: A Population-Based Cohort Study.
Leon SJ; Whitlock R; Rigatto C; Komenda P; Bohm C; Sucha E; Bota SE; Tuna M; Collister D; Sood M; Tangri N
Am J Kidney Dis; 2022 Aug; 80(2):164-173.e1. PubMed ID: 35085685
[TBL] [Abstract][Full Text] [Related]
10. Diabetes and drug-associated hyperkalemia: effect of potassium monitoring.
Raebel MA; Ross C; Xu S; Roblin DW; Cheetham C; Blanchette CM; Saylor G; Smith DH
J Gen Intern Med; 2010 Apr; 25(4):326-33. PubMed ID: 20087674
[TBL] [Abstract][Full Text] [Related]
11. Real-World Associations of Renin-Angiotensin-Aldosterone System Inhibitor Dose, Hyperkalemia, and Adverse Clinical Outcomes in a Cohort of Patients With New-Onset Chronic Kidney Disease or Heart Failure in the United Kingdom.
Linde C; Bakhai A; Furuland H; Evans M; McEwan P; Ayoubkhani D; Qin L
J Am Heart Assoc; 2019 Nov; 8(22):e012655. PubMed ID: 31711387
[TBL] [Abstract][Full Text] [Related]
12. Hyperkalemia and Treatment With RAAS Inhibitors During Acute Heart Failure Hospitalizations and Their Association With Mortality.
Beusekamp JC; Tromp J; Cleland JGF; Givertz MM; Metra M; O'Connor CM; Teerlink JR; Ponikowski P; Ouwerkerk W; van Veldhuisen DJ; Voors AA; van der Meer P
JACC Heart Fail; 2019 Nov; 7(11):970-979. PubMed ID: 31606364
[TBL] [Abstract][Full Text] [Related]
13. Association of Changes in Creatinine and Potassium Levels After Initiation of Renin Angiotensin Aldosterone System Inhibitors With Emergency Department Visits, Hospitalizations, and Mortality in Individuals With Chronic Kidney Disease.
Garlo KG; Bates DW; Seger DL; Fiskio JM; Charytan DM
JAMA Netw Open; 2018 Nov; 1(7):e183874. PubMed ID: 30646338
[TBL] [Abstract][Full Text] [Related]
14. Hyperkalemia in chronic heart failure with renal dysfunction or diabetes mellitus: Results from the TREAT HF study.
Murat S; Kaya H; Çavuşoğlu Y; Yılmaz MB
Turk Kardiyol Dern Ars; 2021 Apr; 49(3):198-205. PubMed ID: 33847269
[TBL] [Abstract][Full Text] [Related]
15. New Therapeutic Approaches for the Treatment of Hyperkalemia in Patients Treated with Renin-Angiotensin-Aldosterone System Inhibitors.
Tamargo J; Caballero R; Delpón E
Cardiovasc Drugs Ther; 2018 Feb; 32(1):99-119. PubMed ID: 29372448
[TBL] [Abstract][Full Text] [Related]
16. [Effect of hyperkalemia and RAASi nonadherence on patients affected by heart failure or chronic kidney disease].
Degli Esposti L; Perrone V; Giacomini E; Sangiorgi D; Alessandrini D; Santoro A
G Ital Nefrol; 2019 Sep; 36(5):. PubMed ID: 31580544
[TBL] [Abstract][Full Text] [Related]
17. Serum Potassium, End-Stage Renal Disease and Mortality in Chronic Kidney Disease.
Nakhoul GN; Huang H; Arrigain S; Jolly SE; Schold JD; Nally JV; Navaneethan SD
Am J Nephrol; 2015; 41(6):456-63. PubMed ID: 26228532
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure).
Eschalier R; McMurray JJ; Swedberg K; van Veldhuisen DJ; Krum H; Pocock SJ; Shi H; Vincent J; Rossignol P; Zannad F; Pitt B;
J Am Coll Cardiol; 2013 Oct; 62(17):1585-93. PubMed ID: 23810881
[TBL] [Abstract][Full Text] [Related]
19. [Hyperkalemia as a limiting factor in the use of drugs that block the Renin Angiotensin Aldosterone System (RAAS)].
Santoro A; Mandreoli M
G Ital Nefrol; 2018 May; 35(3):. PubMed ID: 29786183
[TBL] [Abstract][Full Text] [Related]
20. Risk of hyperkalemia from renin-angiotensin-aldosterone system inhibitors and factors associated with treatment discontinuities in a real-world population.
Wetmore JB; Yan H; Horne L; Peng Y; Gilbertson DT
Nephrol Dial Transplant; 2021 Apr; 36(5):826-839. PubMed ID: 31846025
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
